Division of Maternal-Fetal Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, North Shore University Hospital, Manhasset, NY, USA.
Biostatistics Unit, Feinstein Institute for Medical Research, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, USA.
J Matern Fetal Neonatal Med. 2022 Sep;35(18):3620-3625. doi: 10.1080/14767058.2020.1834532. Epub 2020 Oct 27.
An optimal approach for providing sufficient antenatal surveillance for fetal growth restriction (FGR) has yet to be elucidated. Moreover, there is scant literature on the fetal response to betamethasone and its effect on fetal Dopplers.
To compare persistence of umbilical artery Doppler abnormalities after corticosteroid administration and adverse perinatal outcome in growth restricted fetuses.
Retrospective cohort study (2008-2018) of singleton gestations with FGR (EFW <10th percentile) and umbilical artery Doppler abnormalities (absent or reversed end diastolic velocity) between 24 and 34 weeks of gestation at two institutions. Included patients had Dopplers performed before betamethasone administration and again within 1 week. Excluded were multiple gestations, chromosomal abnormalities, fetal anomalies, or missing outcome information. Pregnancies with persistently abnormal Dopplers were compared with those in which an improvement of Dopplers was noted. The primary outcome was a composite that consisted of indicated preterm birth <32 weeks, 1 or 5 min APGAR score <7, intrauterine fetal demise, and neonatal demise. Secondary outcomes included length of NICU stay, ventilator support, gestational age at delivery, interval between steroids and delivery, and birth weight.
Fifty-three FGR pregnancies met inclusion criteria. Umbilical artery Dopplers improved after steroids in 32% ( = 17). No difference in the frequency of the primary outcome was observed between the persistently abnormal Doppler and improved Doppler groups (72.2% vs. 70.6%, respectively), and there was no difference in any of the secondary outcomes.
Perinatal outcomes in FGR pregnancies were not affected by improved versus persistently abnormal umbilical artery Dopplers after betamethasone administration.
为胎儿生长受限(FGR)提供足够产前监测的最佳方法尚未阐明。此外,关于胎儿对倍他米松的反应及其对胎儿多普勒的影响的文献很少。
比较糖皮质激素治疗后脐动脉多普勒异常的持续存在与生长受限胎儿不良围产结局的关系。
这是一项回顾性队列研究(2008 年至 2018 年),纳入了在两家医院就诊的、妊娠 24 至 34 周且存在 FGR(EFW <第 10 百分位数)和脐动脉多普勒异常(无舒张末期血流或反向)的单胎妊娠。纳入患者在接受倍他米松治疗前和治疗后 1 周内行多普勒检查。排除多胎妊娠、染色体异常、胎儿畸形或缺失围产结局信息的患者。将脐动脉多普勒持续异常的患者与多普勒改善的患者进行比较。主要结局是由<32 周的有指征早产、1 或 5 分钟 Apgar 评分<7、胎儿宫内死亡和新生儿死亡组成的复合结局。次要结局包括新生儿重症监护病房(NICU)住院时间、呼吸机支持、分娩时的胎龄、激素与分娩的间隔时间以及出生体重。
53 例 FGR 妊娠符合纳入标准。32%(17/53)的患者在使用类固醇后脐动脉多普勒得到改善。在持续异常多普勒和改善多普勒组之间,主要结局的发生率无差异(分别为 72.2%和 70.6%),且次要结局也无差异。
在 FGR 妊娠中,在接受倍他米松治疗后,脐动脉多普勒的改善与持续异常对围产结局没有影响。